These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 23211740)

  • 21. Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
    Ryan JM; Wasser JS; Adler AJ; Vella AT
    Expert Opin Biol Ther; 2016; 16(5):655-74. PubMed ID: 26855028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy.
    Jiang CT; Chen KG; Liu A; Huang H; Fan YN; Zhao DK; Ye QN; Zhang HB; Xu CF; Shen S; Xiong MH; Du JZ; Yang XZ; Wang J
    Nat Commun; 2021 Mar; 12(1):1359. PubMed ID: 33649336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity.
    Trivedi S; Jie HB; Ferris RL
    Semin Oncol; 2014 Oct; 41(5):678-84. PubMed ID: 25440612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies.
    Lee SC; López-Albaitero A; Ferris RL
    Curr Oncol Rep; 2009 Mar; 11(2):156-62. PubMed ID: 19216848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutrophils as effector cells for antibody-based immunotherapy of cancer.
    van Egmond M; Bakema JE
    Semin Cancer Biol; 2013 Jun; 23(3):190-9. PubMed ID: 23287459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity.
    Lee SC; Srivastava RM; López-Albaitero A; Ferrone S; Ferris RL
    Immunol Res; 2011 Aug; 50(2-3):248-54. PubMed ID: 21717064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.
    Hamilton G; Rath B
    Expert Opin Biol Ther; 2017 Apr; 17(4):515-523. PubMed ID: 28274143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.
    Yonezawa A; Chester C; Rajasekaran N; Kohrt HE
    Chin Clin Oncol; 2016 Feb; 5(1):5. PubMed ID: 26932429
    [No Abstract]   [Full Text] [Related]  

  • 30. Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.
    Fernández-Marrero Y; López-Requena A
    MAbs; 2011; 3(6):528-34. PubMed ID: 22123064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
    Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
    Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H; Moroyama T; Mendelsohn J
    Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies.
    Taylor RP; Lindorfer MA
    Semin Immunol; 2016 Jun; 28(3):309-16. PubMed ID: 27009480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Future prospects of monoclonal antibodies as magic bullets in immunotherapy.
    Maleki LA; Baradaran B; Majidi J; Mohammadian M; Shahneh FZ
    Hum Antibodies; 2013; 22(1-2):9-13. PubMed ID: 24284304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Redirecting gene-modified T cells toward various cancer types using tagged antibodies.
    Tamada K; Geng D; Sakoda Y; Bansal N; Srivastava R; Li Z; Davila E
    Clin Cancer Res; 2012 Dec; 18(23):6436-45. PubMed ID: 23032741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
    Ascierto PA; Simeone E; Sznol M; Fu YX; Melero I
    Semin Oncol; 2010 Oct; 37(5):508-16. PubMed ID: 21074066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.
    Manieri NA; Chiang EY; Grogan JL
    Trends Immunol; 2017 Jan; 38(1):20-28. PubMed ID: 27793572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibody mechanisms of action in cancer.
    Weiner GJ
    Immunol Res; 2007; 39(1-3):271-8. PubMed ID: 17917071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies in oncology.
    Pillay V; Gan HK; Scott AM
    N Biotechnol; 2011 Sep; 28(5):518-29. PubMed ID: 21473941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.